Despite recent advances in therapies, metastatic castration-resistant prostate cancer (mCRPC) remains incurable with poor prognosis in which novel, more effective treatments are urgently needed. Antibody-drug conjugates (ADCs) are a novel class of agents comprised of a monoclonal antibody directed against a cell surface target of interest that delivers a cytotoxic payload through a cleavable linker. While they have achieved tremendous success in other genitourinary cancers such as urothelial cancer, ADCs have promising activity in mCRPC. In this review, we will provide a high-level overview of ADCs and associated cell surface targets being investigated in mCRPC.
Urologic oncology. 2026 Jul 17 [Epub ahead of print]
Charles B Nguyen, Zachery R Reichert
Department of Medical Oncology & Therapeutics Research, City of Hope Orange County, Irvine, CA. Electronic address: ., Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI.